Emily Bertram

60 days ago

Skinbiotherapeutics fraud enquiry update: this reads very badly

As I have noted many times, to hoots of derision from small furry rodents, Stuart Ashman’s fanboys and other denialists, if the only matter being investigated by FRP at Skinbiotherapeutics (SBTX) was the fraudulent recognition of accrued income from Croda, thus investigation which started in mid February would have been over by March. Today we have an update.

---

101 days ago

Skinbiotherapeutics – what is taking so long?

A few readers pose the question. Shares in Skinbiotherapeutics (SBTX) have now been suspended for almost three weeks as a result of it not being able to get out its accounts for the six months to December 31 while enquiries continue into the fraudulent June 2025 numbers. But why is this taking so long?

---

232 days ago

Stuart Ashman you are a coward: AGM Rule Change & breach of QCA Guidelines

Skinbiotherapeutics (SBTX) insists that it follows the QCA code of corporate governance. But like so much else it says that is simply not true. Now I add to Stuart Ashman’s growing rap sheet a charge of cowardice.

---

233 days ago

Letter to the Financial Reporting Council re Skinbiotherapeutics breaches of IFRS

Laughably Stuart Ashman of Skinbiotherpeutics (SBTX) yesterday praised his bean counter Emily Bertram for her good work and said she’d be promoted for that good work (ching ching for young Emily) in January. This came on a day when June 2025 results finally emerged and contain two material breaches of IFRS. And Emily is being praised and rewarded for her blunders? I have written to my good pals at the FRC…

---

459 days ago

Skinbiotherapeutics: Manprick gone and other boardroom changes, more shares bought

Folks like the Lemming thought that Skinbiotherapeutics (SBTX) FD Manprick Randhawa was the bees knees and were jolly cross with me for rebranding him for his patent incompetence. In my view he was useless, unable to communicate with serious investors or to stop Stuart Ashman abusing the word accretive and, at least, partially responsible for the cack handed and dilutive financing of two acquisitions. He was unable to control costs. Well, today, he has gone to pursue other business interests. Great news.. It has prompted me to buy more shares, increasing my holding by 25%.

---